MedTrace Logo

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

NCT01106716 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-09-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain

Conditions

  • Postherpetic Neuralgia

Interventions

DRUG

Placebo

Placebo IV Infusion

DRUG

KAI-1678

KAI-1678 IV Infusion

DRUG

Lidocaine

Lidocaine

Sponsors & Collaborators

  • Trident Clinical Research Pty Ltd

    collaborator INDUSTRY

  • KAI Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gregory Bell, MD · KAI Pharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-03-31
Completion
2010-04-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01106716 on ClinicalTrials.gov